scholarly journals Significant Increase of HBV Infection in HIV Infected Patients With Disease Progression in China Based on Two MSM HIV Infected Cohorts

2021 ◽  
Author(s):  
Zhiqiang Zhu ◽  
Qi Liang ◽  
Taiyi Jiang ◽  
Yanmei Jiao ◽  
Yu Zhang
Keyword(s):  
Hepatitis B ◽  
Hiv Infection ◽  
Disease Progression ◽  
Hepatitis B Surface Antigen ◽  
Chronic Phase ◽  
Hbv Infection ◽  
Hiv Patients ◽  
Acute Hiv Infection ◽  
Specific Antibodies ◽  
Acute Hiv

Abstract The date about the condition of HBV co infection with the disease progress of HIV is limited. To investigate whether the incidence of HBV co-infection is significantly higher in HIV patients with disease progression in China, we compared rates of HBV co-infection in HIV patients based on an acute and a chronic HIV infected cohort. Significance was assessed with Chi-square. HBV infection is diagnosed by the presence of hepatitis B surface antigen. The HBsAg positive rate increased from 6.18% in acute HIV infection to 11.44% in chronic HIV infection. Thirty-four acute HIV patients had been tested for HBV in their chronic phase, four of them had HBV -specific antigens and/or specific antibodies changes. The number of Hepatitis B virus-specific antibodies decreased from acute phase to chronic phase in four patients and two patients’ HBsAg changed from negative to positive. There is an increased prevalence of HBV infection in HIV patients with the disease progression in China.

scholarly journals Acute HIV Infection Is Beneficial for Controlling Chronic Hepatitis B

2014 ◽  
Vol 60 (1) ◽  
pp. 128-134 ◽  
Author(s):  
Yanmei Jiao ◽  
Ning Li ◽  
Xinyue Chen ◽  
Tong Zhang ◽  
Hongjun Li ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Hiv Infection ◽  
Chronic Hepatitis B ◽  
Acute Hiv Infection ◽  
Acute Hiv

Primary CXCR4 Co-receptor Use in Acute HIV Infection Leads to Rapid Disease Progression in the AE Subtype

2012 ◽  
Vol 25 (4) ◽  
pp. 262-267 ◽  
Author(s):  
Yanmei Jiao ◽  
Yingxue Song ◽  
Buxin Kou ◽  
Rui Wang ◽  
Zhiying Liu ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Disease Progression ◽  
Acute Hiv Infection ◽  
Rapid Disease Progression ◽  
Acute Hiv

scholarly journals Changes in Hepatitis B Virus DNA Levels with Acute HIV Infection

2004 ◽  
Vol 38 (7) ◽  
pp. 1024-1029 ◽  
Author(s):  
Chloe L. Thio ◽  
Dale M. Netski ◽  
Jane Myung ◽  
Eric C. Seaberg ◽  
David L. Thomas
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hiv Infection ◽  
Acute Hiv Infection ◽  
Hepatitis B Virus Dna ◽  
B Virus ◽  
Acute Hiv

How Far we are towards Eradication of HBV Infection

2015 ◽  
Vol 24 (4) ◽  
pp. 473-479 ◽  
Author(s):  
Mihai Voiculescu
Keyword(s):  
Immune Response ◽  
Hepatitis B Virus ◽  
T Cell ◽  
Hepatitis B ◽  
T Cell Receptors ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Major Health Problem ◽  
Cell Receptors ◽  
B Virus

Hepatitis B virus (HBV) infection is a major health problem with an important biological and a significant socio-economic impact all over the world. There is a high pressure to come up with a new and more efficient strategy against HBV infection, especially after the recent success of HCV treatment. Preventing HBV infection through vaccine is currently the most efficient way to decrease HBV-related cirrhosis and liver cancer incidence, as well as the best way to suppress the HBV reservoir. The vaccine is safe and efficient in 80-95% of cases. One of its most important roles is to reduce materno-fetal transmission, by giving the first dose of vaccine in the first 24 hours after birth. Transmission of HBV infection early in life is still frequent, especially in countries with high endemicity.Successful HBV clearance by the host is immune-mediated, with a complex combined innate and adaptive cellular and humoral immune response. Different factors, such as the quantity and the sequence of HBV epitope during processing by dendritic cells and presenting by different HLA molecules or the polymorphism of T cell receptors (TOL) are part of a complex network which influences the final response. A new potential therapeutic strategy is to restore T-cell antiviral function and to improve innate and adaptive immune response by immunotherapeutic manipulation.It appears that HBV eradication is far from being completed in the next decades, and a new strategy against HBV infection must be considered. Abbreviations: ALT: alanine aminotransferase; APC: antigen presenting cells; cccDNA: covalently closed circular DNA; HBIG: hepatitis B immunoglobulin; HbsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; CTL: cytotoxic T lymphocyte; IFN: interferon; NUC: nucleos(t)ide analogues; pg RNA: pre genomic RNA; TLR: toll-like receptors; TOL: T cell receptors.

scholarly journals Protective HLA alleles are associated with reduced LPS levels in acute HIV infection with implications for immune activation and pathogenesis

2019 ◽  
Vol 15 (8) ◽  
pp. e1007981 ◽  
Author(s):  
Daniel T. Claiborne ◽  
Eileen P. Scully ◽  
Christine D. Palmer ◽  
Jessica L. Prince ◽  
Gladys N. Macharia ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Immune Activation ◽  
Acute Hiv Infection ◽  
Hla Alleles ◽  
Acute Hiv

scholarly journals 1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S562-S562
Author(s):  
Robert Gish ◽  
Vincent Streva
Keyword(s):  
Hepatitis B ◽  
Immune Escape ◽  
Hepatitis B Surface Antigen ◽  
Panel Member ◽  
The United States ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Review Panel ◽  
B Virus ◽  
Escape Mutants

Abstract Background Although overall infection rates of Hepatitis B virus (HBV) in the United States (US) remain stable, as many as 2.2 million persons are still chronically infected with Hepatitis B Virus (HBV)1. Persons who inject drugs (PWID) are at a higher risk of HBV infection and since 2009 three states (KY, TN, WV) have reported up to a 114% increase in cases of acute HBV infection due to higher infection rates among a non-Hispanic white populations (30–39 years), and injection drug users2. Hepatitis B vaccination is recommended as primary prevention for adults who are at increased risk for HBV infection, including PWID. However, data from the National Health Interview Survey indicate that hepatitis B vaccination coverage is low among adults in the general population3, and it is likely to be lower among injection drug users. Hepatitis B Surface Antigen (HBsAg) is the first serological marker to appear after HBV exposure and infection; this marker is included in the recommended panel for acute hepatitis diagnosis and accurate detection is necessary for early and accurate diagnosis. Serological testing challenges exist for HBsAg due to the high degree of genetic variability which can further be exacerbated by endogenous and exogenous pressures. The immuno-dominant region may have one or more mutations described as immune escape mutations which can decrease or abrogate HBsAg binding to antibodies used in immunoassays. Although the prevalence of these mutations is not well documented in the United States, international studies have shown that up to 79% of HBV-reactivated patients (vs 3.1% of control patients; p< 0.001) carry HBsAg mutations localized in immune-active HBsAg regions4. Methods A study was conducted using a panel of 10 unique recombinant HBsAg immune escape mutants. Panel members were tested by commercially available HBsAg serological immunoassays. Results It was found that although commercially available HBsAg immunoassays are the primary diagnostic tool for HBV diagnosis, not all HBsAg immune escape mutants are detected, with some method detecting as few as 5 out of 10 of these mutant samples. Figure 1 Conclusion Improvement is needed in commercially available methods for the accurate detection of HBsAg. Disclosures Robert Gish, MD, Abbott (Consultant)AbbVie (Consultant, Advisor or Review Panel member, Speaker’s Bureau)Access Biologicals (Consultant)Antios (Consultant)Arrowhead (Consultant)Bayer (Consultant, Speaker’s Bureau)Bristol Myers (Consultant, Speaker’s Bureau)Dova (Consultant, Speaker’s Bureau)Dynavax (Consultant)Eiger (Consultant, Advisor or Review Panel member)Eisai (Consultant, Speaker’s Bureau)Enyo (Consultant)eStudySite (Consultant, Advisor or Review Panel member)Exelixis (Consultant)Fujifilm/Wako (Consultant)Genentech (Consultant)Genlantis (Consultant)Gilead (Consultant, Advisor or Review Panel member, Speaker’s Bureau)GLG (Consultant)HepaTX (Consultant, Advisor or Review Panel member)HepQuant (Consultant, Advisor or Review Panel member)Intercept (Consultant, Speaker’s Bureau)Ionis (Consultant)Janssen (Consultant)Laboratory for Advanced Medicine (Consultant)Lilly (Consultant)Merck (Consultant)Salix (Consultant, Speaker’s Bureau)Shionogi (Consultant, Speaker’s Bureau)Viking (Consultant)

Sign in / Sign up

Export Citation Format

Share Document